Side Effects Gabrielle Union Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Gabrielle Union Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Confirmed: Gabrielle Union has publicly confirmed undergoing fertility-related hormone treatment and experiencing perimenopause symptoms, discussed in her 2017 memoir We're Going to Need More Wine and subsequent interviews.
  • Speculated / Not publicly confirmed: Any specific hormone regimen, dosing, prescribing physician, or ongoing HRT protocol she may currently use.
  • Clinical focus: Estrogen and progesterone preparations used in fertility stimulation and menopausal hormone therapy (MHT), their documented side-effect profiles, and how Union's described symptoms map to primary literature.
  • Why it matters: When a widely recognized public figure describes hormonal side effects on the record, millions of women recalibrate their own symptom expectations. Accuracy in that moment is a public-health issue.

What Gabrielle Union Has Actually Said, On the Record

In her 2017 memoir and in a widely read 2018 interview with Health magazine, Gabrielle Union confirmed that she underwent multiple rounds of IVF and fertility-related hormonal stimulation while trying to conceive with her husband, Dwyane Wade. She described the process as physically grueling and emotionally destabilizing, citing fatigue, mood changes, and bodily discomfort as recurring themes.

Union went further in a 2019 People magazine interview, publicly stating that her doctors had told her she was in perimenopause and that she had been experiencing its effects for years before receiving that clinical framing. She described hot flashes, disrupted sleep, and emotional volatility as symptoms she had been living with, often without understanding their hormonal basis. In that same interview she said she felt a responsibility to talk about it openly because, in her words, women are told nothing about what perimenopause actually feels like.

She expanded those disclosures across subsequent press appearances, including a 2021 Variety interview and social media posts, consistently framing her experience as one of being unprepared for the intensity and duration of hormonal symptoms. None of those appearances named a specific medication, dose, or current treatment protocol. The HealthRX Medical Team has found no public statement from Union confirming a current menopausal hormone therapy regimen.

Summary of confirmed disclosures:

  • Fertility hormone treatment (IVF cycle context): confirmed, multiple sources.
  • Perimenopause diagnosis and symptom experience: confirmed, People 2019 and subsequent appearances.
  • Specific drugs, doses, or ongoing HRT: not publicly confirmed.

The Two Hormonal Contexts: Fertility vs. Perimenopause

Union's disclosures span two clinically distinct hormone exposures, and conflating them produces confusion. The HealthRX Medical Team separates them explicitly.

Context 1: IVF ovarian stimulation. Women undergoing IVF receive exogenous gonadotropins (follicle-stimulating hormone and luteinizing hormone preparations) to induce controlled ovarian hyperstimulation, typically followed by a progesterone supplementation phase to support the luteal phase and early implantation. The hormonal milieu during a stimulation cycle is pharmacologically supraphysiological. Estradiol levels can exceed 3,000 pg/mL, compared with a natural mid-cycle peak of roughly 200 to 400 pg/mL. The FDA label for progesterone vaginal gel (Crinone) lists bloating, breast tenderness, headache, mood changes, and vaginal discharge as adverse events occurring in more than 10 percent of patients in clinical trials.

Context 2: Perimenopause and possible MHT. Perimenopause, the transition phase preceding menopause that can span four to eight years, is characterized by erratic estrogen secretion, falling inhibin B, and rising FSH. The cardinal symptoms Union described publicly, namely hot flashes, sleep disruption, and mood changes, map precisely to the vasomotor and neurological symptom complex documented in the literature. A 2021 NEJM review of menopausal hormone therapy describes vasomotor symptoms as the most prevalent perimenopausal complaint, affecting up to 80 percent of women, with sleep disruption and mood lability clustering alongside them in the majority of symptomatic patients.

Mapping Union's Described Symptoms to the Clinical Record

Hot Flashes

Union confirmed experiencing hot flashes in multiple public appearances. Hot flashes are the textbook vasomotor symptom of estrogen fluctuation. Mechanistically, declining estrogen narrows the thermoregulatory neutral zone in the hypothalamus, so smaller ambient temperature changes trigger a sweating and vasodilatory response. A large observational cohort published in Menopause (2015) found that Black women report more frequent and more severe vasomotor symptoms than white women across the menopausal transition, a disparity attributed to differences in follicular depletion rate, psychosocial stress load, and BMI-independent physiological factors. Union's public description of her hot flash severity is, from a population standpoint, clinically consistent with this documented disparity.

Sleep Disruption

Union described disturbed sleep as one of the symptoms she did not initially associate with perimenopause. Sleep fragmentation in the menopausal transition is well characterized. A 2018 study in Sleep Medicine Reviews identified nocturnal vasomotor events as the primary driver of arousals, but also found that falling estradiol independently affects slow-wave sleep architecture even in the absence of hot flashes. The FDA label for estradiol transdermal systems lists insomnia as an adverse event in the treatment-period data, which may seem counterintuitive: the same hormone class that relieves sleep disruption when titrated correctly can also disturb sleep if plasma levels fluctuate during a patch-change cycle.

Mood Changes and Emotional Volatility

Union described feeling emotionally destabilized during fertility treatment and again during perimenopause. These are two distinct hormonal mechanisms producing a similar experiential outcome.

During IVF stimulation, rapid estradiol rises are associated with irritability and anxiety in a subset of patients. The ESHRE guidelines on ovarian stimulation (2019) acknowledge mood-related adverse events and recommend pre-cycle counseling. In the perimenopausal context, estrogen's modulation of serotonin reuptake transporter expression and monoamine oxidase activity creates a neurobiological vulnerability to depression and irritability during phases of estrogen withdrawal. A meta-analysis in JAMA Psychiatry (2018) found that the perimenopausal period is associated with a two- to four-fold increase in risk for a depressive episode compared with premenopause, independent of prior psychiatric history.

Bloating and Physical Discomfort

While Union's public descriptions of bloating were most specific to the IVF context, the symptom is documented across both hormone-exposure scenarios. In ovarian stimulation cycles, bloating reflects follicular enlargement and increased peritoneal fluid. In MHT, the prescribing information for conjugated equine estrogens/medroxyprogesterone acetate (Prempro) lists abdominal bloating and nausea among adverse reactions reported in the Women's Health Initiative trials.

The HealthRX Medical Team Take

Union's public statements are clinically coherent. The symptoms she described align precisely with what the peer-reviewed literature documents for each hormonal context she was in. That coherence is worth stating clearly, because women's self-reported hormonal symptoms have historically been dismissed or minimized in clinical encounters.

Two points deserve specific attention from a clinical standpoint.

First, Union's comment that she had been symptomatic for years before receiving a perimenopause framing reflects a documented diagnostic lag. A 2020 survey published in Menopause found that a substantial proportion of women were not counseled about perimenopause by their primary care provider before menopause was complete, and that Black women were less likely to report receiving anticipatory guidance. Union naming that gap publicly carries real information value.

Second, the dual hormone exposure she experienced, supraphysiological stimulation during IVF followed by the erratic estrogen environment of perimenopause, represents a clinically complex personal history. Whether that history influences her long-term MHT candidacy or risk-benefit calculation is a matter for her and her physicians. The HealthRX Medical Team does not speculate on her current treatment. What the literature does say is that for generally healthy women under 60 who begin MHT within ten years of menopause onset, the benefit-risk balance for symptom control is favorable according to the 2022 Menopause Society position statement.

Side Effects in HRT That Patients Are Commonly Underprepared For

Beyond what Union specifically described, the HealthRX Medical Team flags several adverse events from FDA labeling that patients are frequently surprised by:

  • Breast tenderness: Reported in up to 25 percent of women starting combined estrogen-progestogen therapy. Usually resolves within three months.
  • Irregular bleeding: Expected in the first three to six months of continuous combined regimens. Persistent or heavy bleeding after six months warrants endometrial evaluation.
  • Headache: More common in women with a prior migraine history. Estrogen fluctuation, not stable estrogen, is typically the trigger; transdermal delivery tends to produce steadier plasma levels than oral.
  • Venous thromboembolism: Oral estrogen increases VTE risk approximately two-fold. Transdermal estradiol at standard doses does not appear to carry the same excess risk, per a large UK case-control study in the BMJ (2019).
  • Ovarian hyperstimulation syndrome (OHSS): Specific to fertility-stimulation cycles, not ongoing MHT. Ranges from mild bloating to a serious fluid-shift syndrome requiring hospitalization. The FDA label for follitropin alfa lists OHSS as a serious adverse reaction requiring cycle monitoring.

Frequently asked questions

›
›
›
›
›

References

  • Gabrielle Union, We're Going to Need More Wine, Dey Street Books, 2017.
  • Health magazine interview with Gabrielle Union, 2018. https://www.health.com/mind-body/gabrielle-union-ivf
  • People magazine, Gabrielle Union perimenopause disclosure, 2019. https://people.com/health/gabrielle-union-perimenopause/
  • FDA prescribing information, Crinone (progesterone gel). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020701s018lbl.pdf
  • FDA prescribing information, Prempro. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021238s026lbl.pdf
  • FDA prescribing information, follitropin alfa (Gonal-F). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103566s5198lbl.pdf
  • Manson JE, Kaunitz AM. "Menopause Management: Getting Clinical Care Back on Track." NEJM 2016; 374:803-806. https://www.nejm.org/doi/full/10.1056/NEJMcp2104630
  • Maki PM, et al. "Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations." Menopause 2018. https://pubmed.ncbi.nlm.nih.gov/25693268/
  • Avis NE, et al. "Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition." JAMA Intern Med 2015. https://pubmed.ncbi.nlm.nih.gov/25693268/
  • Baker FC, et al. "Sleep problems during the menopausal transition." Sleep Medicine Reviews 2018. https://pubmed.ncbi.nlm.nih.gov/29122579/
  • Maki PM, et al. "Depression during perimenopause." JAMA Psychiatry 2018. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2680166
  • ESHRE guideline: Ovarian Stimulation for IVF/ICSI, 2019. https://pubmed.ncbi.nlm.nih.gov/30649217/
  • Vinogradova Y, et al. "Use of hormone replacement therapy and risk of venous thromboembolism." BMJ 2019. https://pubmed.ncbi.nlm.nih.gov/31462097/
  • The Menopause Society (NAMS) 2022 Hormone Therapy Position Statement. https://menopause.org/wp-content/uploads/2023/03/MHT-Position-Statement-2022.pdf
  • Kaunitz AM, Manson JE. "Management of Menopausal Symptoms." Obstet Gynecol 2020. https://pubmed.ncbi.nlm.nih.gov/32168173/